scholarly journals A thirty-nine-year survival with the Starr-Edwards mitral valve prosthesis

2016 ◽  
Vol 70 (1) ◽  
Author(s):  
Sabino Scardi ◽  
Bruno Pinamonti ◽  
Michele Moretti ◽  
Gianfranco Sinagra
Keyword(s):  
Mitral Valve ◽  
Valve Replacement ◽  
Mitral Valve Replacement ◽  
Major Bleeding ◽  
Valve Prosthesis ◽  
Tricuspid Valve Replacement ◽  
High Tendency ◽  
Mitral Valve Prosthesis ◽  
Edwards Model ◽  
Hemodynamic Performance

We report a case of a 57 year-old woman with Starr- Edwards model 6120 mitral valve replacement and Kay- Shiley bioprosthetic tricuspid valve replacement in 1968 at Niguarda Hospital in Milan. The mitral caged-ball has proved its excellent durability and its good hemodynamic performance in many patients, even if subject to high tendency to thrombosis. In literature there is no evidence of durability of this prosthesis longer than 35 years. Our patient after 39 years from mitral valve replacement lives a happy and fulfilling life (NYHA II), with no evidence of hemolysis, ball variance, symptomatic embolization or major bleeding.

Acute Thrombotic Obstruction of Mitral Valve Prosthesis: Low Protein C Level

2002 ◽  
Vol 10 (2) ◽  
pp. 165-166 ◽  
Author(s):  
Toshihiro Ohata ◽  
Tetsuo Sakakibara ◽  
Hiroshi Takano ◽  
Toru Ishizaka
Keyword(s):  
Mitral Valve ◽  
Valve Replacement ◽  
Mitral Valve Replacement ◽  
Protein C ◽  
Mechanical Valve ◽  
Protein S ◽  
Valve Prosthesis ◽  
Normal Value ◽  
Low Protein ◽  
Mitral Valve Prosthesis

A 51-year-old female underwent redo mitral valve replacement with a pericardial bioprosthesis because of acute thrombotic obstruction of a mechanical valve, in spite of adequate anticoagulation with warfarin. Her protein C level was 24% of the normal value and protein S was reduced to 54% of normal.

Transcatheter Aortic Valve Implantation after Previous Mechanical Mitral Valve Replacement: Expanding Indications?

2011 ◽  
Vol 14 (3) ◽  
pp. 166 ◽  
Author(s):  
Carsten J. Beller ◽  
Raffi Bekeredjian ◽  
Ulrike Krumsdorf ◽  
R�diger Leipold ◽  
Hugo A. Katus ◽  
...  
Keyword(s):  
High Risk ◽  
Mitral Valve ◽  
Aortic Valve ◽  
Valve Replacement ◽  
Mitral Valve Replacement ◽  
Severe Aortic Stenosis ◽  
Valve Prosthesis ◽  
Transcatheter Aortic Valve ◽  
Mitral Valve Prosthesis ◽  
Risk Patients

<p><b>Background:</b> Cardiac operation for severe aortic stenosis after previous mitral valve replacement is a surgical challenge in older patients with multiple morbidities. Transcatheter aortic valve implantation (TAVI) after previous mechanical mitral valve replacement has been considered a high-risk procedure, owing to possible interference with the mitral valve prosthesis.</p><p><b>Methods:</b> Since August 2008, 5 female high-risk patients with severe aortic stenosis and previous mitral valve replacement (mean � SD age, 80 � 5.1 years; logistic EuroSCORE, 39.3% � 20.5%) underwent TAVI with a pericardial xenograft valve that was fixed with a stainless steel, balloon-expandable stent (Edwards Lifesciences SAPIEN). We used a transapical approach in 4 patients and a transfemoral approach in 1 patient. Transesophageal echocardiography and multidetector computed tomography were used for preoperative planning and assessment of operation feasibility. The mean distance between the aortic annulus and the mitral valve prosthesis was 10 � 1 mm (range, 9-11 mm).</p><p><b>Results:</b> TAVI was performed successfully in all 5 patients. There was no direct or functional interference with the mechanical mitral valve prostheses. Echocardiography revealed good valve function with no more than mild paravalvular incompetence early in the postoperative period and during routine follow-up. There were no neurologic events. After an initially uneventful course with good aortic valve function at the most recent echocardiography evaluation, however, 2 of the patients died from fulminant pneumonia on postoperative days 4 and 48.</p><p><b>Conclusion:</b> TAVI is technically feasible in high-risk patients after previous mechanical mitral valve replacement; however, careful patient selection is mandatory with respect to preoperative clinical status and anatomic dimensions regarding the distance between aortic annulus and mitral valve prosthesis.</p>

Sign in / Sign up

Export Citation Format

Share Document